IDEAS home Printed from https://ideas.repec.org/h/elg/eechap/14021_45.html
   My bibliography  Save this book chapter

Future Costs in Medical Cost-effectiveness Analysis

In: The Elgar Companion to Health Economics, Second Edition

Author

Listed:
  • David Meltzer

Abstract

This comprehensive collection brings together more than 50 contributions from some of the most influential researchers in health economics. It authoritatively covers theoretical and empirical issues in health economics, with a balanced range of material on equity and efficiency in health care systems, health technology assessment and issues of concern for developing countries. This thoroughly revised second edition is expanded to include four new chapters, while all existing chapters have been extensively updated.

Suggested Citation

  • David Meltzer, 2012. "Future Costs in Medical Cost-effectiveness Analysis," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 45, Edward Elgar Publishing.
    • Handle: RePEc:elg:eechap:14021_45
    as

    Download full text from publisher

    File URL: https://www.elgaronline.com/view/9781849802673.00062.xml
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Lee, Robert H., 2008. "Thinking rigorously about future costs in cost effectiveness analysis," Journal of Health Economics, Elsevier, vol. 27(6), pages 1650-1651, December.
    2. Werner B.F. Brouwer & Frans F.H. Rutten, 2003. "The missing link: on the line between C and E," Health Economics, John Wiley & Sons, Ltd., vol. 12(8), pages 629-636, August.
    3. Blomqvist, Ake, 2002. "QALYs, standard gambles, and the expected budget constraint," Journal of Health Economics, Elsevier, vol. 21(2), pages 181-195, March.
    4. Lee, Robert H., 2008. "Future costs in cost effectiveness analysis," Journal of Health Economics, Elsevier, vol. 27(4), pages 809-818, July.
    5. John A. Nyman, 2004. "Should the consumption of survivors be included as a cost in cost–utility analysis?," Health Economics, John Wiley & Sons, Ltd., vol. 13(5), pages 417-427, May.
    6. Garber, Alan M. & Phelps, Charles E., 1997. "Economic foundations of cost-effectiveness analysis," Journal of Health Economics, Elsevier, vol. 16(1), pages 1-31, February.
    7. Weinstein, Milton & Zeckhauser, Richard, 1973. "Critical ratios and efficient allocation," Journal of Public Economics, Elsevier, vol. 2(2), pages 147-157, April.
    8. Feenstra, Talitha L. & van Baal, Pieter H.M. & Gandjour, Afshin & Brouwer, Werner B.F., 2008. "Future costs in economic evaluation: A comment on Lee," Journal of Health Economics, Elsevier, vol. 27(6), pages 1645-1649, December.
    9. Braden Manns & David Meltzer & Ken Taub & Cam Donaldson, 2003. "Illustrating the impact of including future costs in economic evaluations: an application to end‐stage renal disease care," Health Economics, John Wiley & Sons, Ltd., vol. 12(11), pages 949-958, November.
    10. Magnus Johannesson & David Meltzer, 1998. "Editorial: Some reflections on cost‐effectiveness analysis," Health Economics, John Wiley & Sons, Ltd., vol. 7(1), pages 1-7, February.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Kellerborg, Klas & Wouterse, Bram & Brouwer, Werner & van Baal, Pieter, 2021. "Estimating the costs of non-medical consumption in life-years gained for economic evaluations," Social Science & Medicine, Elsevier, vol. 289(C).
    2. Pieter H. M. van Baal & Talitha L. Feenstra & Johan J. Polder & Rudolf T. Hoogenveen & Werner B. F. Brouwer, 2011. "Economic evaluation and the postponement of health care costs," Health Economics, John Wiley & Sons, Ltd., vol. 20(4), pages 432-445, April.
    3. Alec Morton & Amanda I. Adler & David Bell & Andrew Briggs & Werner Brouwer & Karl Claxton & Neil Craig & Alastair Fischer & Peter McGregor & Pieter van Baal, 2016. "Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal," Health Economics, John Wiley & Sons, Ltd., vol. 25(8), pages 933-938, August.
    4. Marie Kruse & Jan Sørensen & Dorte Gyrd-Hansen, 2012. "Future costs in cost-effectiveness analysis: an empirical assessment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(1), pages 63-70, February.
    5. Pieter H. M. van Baal & Talitha L. Feenstra & Rudolf T. Hoogenveen & G. Ardine de Wit & Werner B. F. Brouwer, 2007. "Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a ‘perfect’ cost–utility ratio," Health Economics, John Wiley & Sons, Ltd., vol. 16(4), pages 421-433, April.
    6. Pieter van Baal & David Meltzer & Werner Brouwer, 2016. "Future Costs, Fixed Healthcare Budgets, and the Decision Rules of Cost‐Effectiveness Analysis," Health Economics, John Wiley & Sons, Ltd., vol. 25(2), pages 237-248, February.
    7. Dieter Tscheulin & Florian Drevs, 2010. "The relevance of unrelated costs internal and external to the healthcare sector to the outcome of a cost-comparison analysis of secondary prevention: the case of general colorectal cancer screening in," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(2), pages 141-150, April.
    8. Amiram Gafni, 2006. "Economic Evaluation of Health-care Programmes: Is CEA Better than CBA?," Environmental & Resource Economics, Springer;European Association of Environmental and Resource Economists, vol. 34(3), pages 407-418, July.
    9. Basu, Anirban, 2020. "A welfare-theoretic model consistent with the practice of cost-effectiveness analysis and its implications," Journal of Health Economics, Elsevier, vol. 70(C).
    10. Bengt Liljas, 2010. "On the welfare theoretic foundation of cost-effectiveness analysis—the case when survival is not affected," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(1), pages 5-13, February.
    11. An Creemers & Marc Aerts & Niel Hens & Ziv Shkedy & Frank De Smet & Philippe Beutels, 2011. "Revealing age-specific past and future unrelated costs of pneumococcal infections by flexible generalized estimating equations," Journal of Applied Statistics, Taylor & Francis Journals, vol. 38(8), pages 1533-1547, August.
    12. Bengt Liljas, 2011. "Welfare, QALYs, and costs – a comment," Health Economics, John Wiley & Sons, Ltd., vol. 20(1), pages 68-72, January.
    13. Ryen, Linda & Svensson, Mikael, 2014. "The Willingness to Pay for a QALY: a Review of the Empirical Literature," Karlstad University Working Papers in Economics 12, Karlstad University, Department of Economics.
    14. Mark Sculpher & David Torgerson & Ron Goeree & Bernie O'Brien, 1999. "A critical structured review of economic evaluations of interventions for the prevention and treatment of osteoporosis," Working Papers 169chedp, Centre for Health Economics, University of York.
    15. Basu, Anirban, 2015. "Welfare implications of learning through solicitation versus diversification in health care," Journal of Health Economics, Elsevier, vol. 42(C), pages 165-173.
    16. Liqun Liu & Andrew J. Rettenmaier & Thomas R. Saving, 2012. "Endogenous Patient Responses and the Consistency Principle in Cost-Effectiveness Analysis," Medical Decision Making, , vol. 32(3), pages 488-497, May.
    17. Grassi, Simona & Ma, Ching-to Albert, 2011. "Optimal public rationing and price response," Journal of Health Economics, Elsevier, vol. 30(6), pages 1197-1206.
    18. Charles Christian Adarkwah & Amirhossein Sadoghi & Afschin Gandjour, 2016. "Should Cost‐Effectiveness Analysis Include the Cost of Consumption Activities? AN Empirical Investigation," Health Economics, John Wiley & Sons, Ltd., vol. 25(2), pages 249-256, February.
    19. Klas Kellerborg & Werner Brouwer & Matthijs Versteegh & Bram Wouterse & Pieter van Baal, 2021. "Distributional consequences of including survivor costs in economic evaluations," Health Economics, John Wiley & Sons, Ltd., vol. 30(10), pages 2606-2613, September.
    20. Daniel Grima & Lisa Bernard & Elizabeth Dunn & Philip McFarlane & David Mendelssohn, 2012. "Cost-Effectiveness Analysis of Therapies for Chronic Kidney Disease Patients on Dialysis," PharmacoEconomics, Springer, vol. 30(11), pages 981-989, November.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:elg:eechap:14021_45. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Darrel McCalla (email available below). General contact details of provider: http://www.e-elgar.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.